Global Cord Blood (NYSE:CO) and Greenbrook TMS (NASDAQ:GBNH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.
Valuation and Earnings
This table compares Global Cord Blood and Greenbrook TMS’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Global Cord Blood||$176.99 million||3.15||$77.57 million||N/A||N/A|
|Greenbrook TMS||$43.13 million||3.16||-$29.66 million||($2.32)||-3.65|
This is a breakdown of current ratings and recommmendations for Global Cord Blood and Greenbrook TMS, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Global Cord Blood||0||0||0||0||N/A|
Greenbrook TMS has a consensus price target of $16.13, suggesting a potential upside of 90.38%. Given Greenbrook TMS’s higher probable upside, analysts clearly believe Greenbrook TMS is more favorable than Global Cord Blood.
This table compares Global Cord Blood and Greenbrook TMS’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Global Cord Blood||42.87%||11.81%||6.54%|
Insider and Institutional Ownership
9.9% of Global Cord Blood shares are held by institutional investors. Comparatively, 6.1% of Greenbrook TMS shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Global Cord Blood beats Greenbrook TMS on 7 of the 10 factors compared between the two stocks.
Global Cord Blood Company Profile
Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.
Greenbrook TMS Company Profile
Greenbrook Tms, Inc. engages in the provision of transcranial magnetic stimulation, an FDA-cleared, non-invasive therapy for the treatment of major depressive disorder. The company was founded on February 9, 2018 and is headquartered in Toronto, Canada.
Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.